Acadia Pharmaceuticals Inc. (ACAD) announced on Thursday the outcomes of its LILAC-1 and LILAC-2 studies, which demonstrated improvement in patients with Rett syndrome. This improvement was assessed using the Rett Syndrome Behaviour Questionnaire.
Rett syndrome is a rare and complex neurodevelopmental disorder characterized by symptoms such as unusual hand movements, mobility challenges, and gait abnormalities.
The LILAC-1 study evaluated the long-term safety and efficacy of Daybue in patients aged five to 21 years with Rett syndrome. Meanwhile, the LILAC-2 study focused on the long-term safety and efficacy of Daybue in females aged five to 22 years who had completed the LILAC-1 study, according to the company.
The findings, published in the journal Med, indicated that Daybue's safety profile aligned with the results from the LAVENDER trial. However, common side effects such as diarrhea and vomiting were observed during the studies.
As of now, Acadia's stock has decreased by 1.25 percent to $18.12 on the Nasdaq.
